View More Recent Stories

May 6, 2019 05:49AM Cytokinetics (CYTK) Reports Results of FORTITUDE-ALS, a Phase 2 Clinical Trial of Reldesemtiv in Patients With ALS at AAN 2019 Meetings
May 5, 2019 01:11PM Cytokinetics Announces Results of FORTITUDE-ALS, a Phase 2 Clinical Trial of Reldesemtiv in Patients With ALS, Presented at American Academy of Neurology Annual Meeting
Apr 25, 2019 04:00PM Cytokinetics to Announce First Quarter Results on May 9, 2019
Apr 1, 2019 04:00PM Cytokinetics to Present at April Investor Conferences
Mar 20, 2019 08:33AM Amgen (AMGN) Cytokinetics, Inc. (CYTK) and Servier Report Continuation Of GALACTIC-HF Following Planned Interim Analysis
Mar 20, 2019 08:30AM Amgen, Cytokinetics and Servier Announce Continuation of GALACTIC-HF Following Planned Interim Analysis
Mar 20, 2019 08:30AM Amgen, Cytokinetics And Servier Announce Continuation Of GALACTIC-HF Following Planned Interim Analysis
Mar 18, 2019 04:13PM Cytokinetics (CYTK) Announces Presentation of Additional Results From COSMIC-HF at ACC
Mar 18, 2019 04:00PM Cytokinetics Announces Presentation of Additional Results From COSMIC-HF at ACC.19
Mar 11, 2019 12:04PM Cytokinetics Announces Additional Results From COSMIC-HF to be Presented at ACC.19
Mar 7, 2019 04:10PM Cytokinetics Announces Presentation of Results From FORTITUDE-ALS at the American Academy of Neurology 71st Annual Meeting
Feb 28, 2019 07:30AM Cytokinetics Joins Global Initiative To Recognize International Rare Disease Day
Feb 21, 2019 08:37AM Amgen (AMGN) Cytokinetics (CYTK) & Servier Report Start of METEORIC-HF, the Second Phase 3 Clinical Trial Of Omecamtiv Mecarbil In Patients with Heart Failure
Feb 21, 2019 08:30AM Amgen, Cytokinetics And Servier Announce Start Of METEORIC-HF, The Second Phase 3 Clinical Trial Of Omecamtiv Mecarbil In Patients With Heart Failure
Feb 21, 2019 08:30AM Amgen, Cytokinetics and Servier Announce Start of METEORIC-HF, the Second Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients With Heart Failure
Feb 20, 2019 09:02AM Cytokinetics (CYTK) Commences Phase 1 Clinical Study of AMG 594
Feb 20, 2019 09:00AM Cytokinetics Announces Initiation of Phase 1 Clinical Study of AMG 594, a Cardiac Troponin Activator
Feb 7, 2019 04:00PM Cytokinetics to Announce Fourth Quarter Results on February 21, 2019
Jan 22, 2019 07:32AM Cytokinetics (CYTK) Receives FDA Feedback Regarding Reldesemtiv in Patients With SMA, Six Minute Walk Test Acceptable as Primary Efficacy Endpoint
Jan 22, 2019 07:30AM Cytokinetics Announces Receipt of FDA Feedback Regarding Reldesemtiv in Patients With SMA
Dec 10, 2018 07:30AM Cytokinetics Announces New Data Presented at the International Symposium on ALS/MND
Dec 5, 2018 07:30AM Cytokinetics Announces Initiation of Phase 1 Clinical Trial of CK-3773274, a Cardiac Myosin Inhibitor
Nov 27, 2018 07:45AM Cytokinetics (CYTK) Reports Complete Enrollment in FORTITUDE-ALS, Phase 2 Clinical Trial of Reldesemtiv in Patients With ALS
Nov 27, 2018 07:30AM Cytokinetics Completes Enrollment in FORTITUDE-ALS, Phase 2 Clinical Trial of Reldesemtiv in Patients With ALS
Nov 26, 2018 04:00PM Cytokinetics Announces Five Presentations at the International Symposium on ALS/MND
Dec 1, 2016 06:36AM Amgen (AMGN), Cytokinetics (CYTK) Announce Publication of Significant Omecamtiv Mecarbil Phase 2 Data
Nov 30, 2016 06:31PM The Lancet Publishes Results From COSMIC-HF Trial Showing Omecamtiv Mecarbil Significantly Improved Cardiac Function In Patients With Chronic Heart Failure
Nov 30, 2016 06:30PM The Lancet Publishes Results From COSMIC-HF Trial Showing Omecamtiv Mecarbil Significantly Improved Cardiac Function in Patients With Chronic Heart Failure
Apr 29, 2016 10:00AM Cytokinetics, Inc. (Nasdaq: CYTK) to Ring The Nasdaq Stock Market Closing Bell
Nov 8, 2015 03:45PM Amgen And Cytokinetics Announce Late-Breaking Presentation Of COSMIC-HF Trial At AHA Scientific Sessions 2015
Nov 8, 2015 03:45PM Amgen and Cytokinetics Announce Late-Breaking Presentation of COSMIC-HF Trial at AHA Scientific Sessions 2015
Oct 27, 2015 08:00AM Amgen and Cytokinetics Announce Positive Top-Line Results From COSMIC-HF, A Phase 2 Trial of Omecamtiv Mecarbil in Patients With Chronic Heart Failure
Oct 27, 2015 08:00AM Amgen and Cytokinetics Announce Positive Top-Line Results From COSMIC-HF, a Phase 2 Trial of Omecamtiv Mecarbil in Patients With Chronic Heart Failure
Jul 14, 2015 12:17PM Streetinsider.com's Hot Lunchtime Reads 7/14: (TWTR) (IACI) (MSFT) (CYTK)
View More Recent Stories